Cargando…

Lowered anti-beta1 adrenergic receptor antibody concentrations may have prognostic significance in acute coronary syndrome

Although several risk factors exist for acute coronary syndrome (ACS) no biomarkers for survival or risk of re-infarction have been validated. Previously, reduced serum concentrations of anti-ß(1)AR Ab have been implicated in poorer ACS outcomes. This study further evaluates the prognostic implicati...

Descripción completa

Detalles Bibliográficos
Autores principales: Ernst, Diana, Westerbergh, Johan, Sogkas, Georgios, Jablonka, Alexandra, Ahrenstorf, Gerrit, Schmidt, Reinhold Ernst, Heidecke, Harald, Wallentin, Lars, Riemekasten, Gabriela, Witte, Torsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6787077/
https://www.ncbi.nlm.nih.gov/pubmed/31601947
http://dx.doi.org/10.1038/s41598-019-51125-9
_version_ 1783458185010479104
author Ernst, Diana
Westerbergh, Johan
Sogkas, Georgios
Jablonka, Alexandra
Ahrenstorf, Gerrit
Schmidt, Reinhold Ernst
Heidecke, Harald
Wallentin, Lars
Riemekasten, Gabriela
Witte, Torsten
author_facet Ernst, Diana
Westerbergh, Johan
Sogkas, Georgios
Jablonka, Alexandra
Ahrenstorf, Gerrit
Schmidt, Reinhold Ernst
Heidecke, Harald
Wallentin, Lars
Riemekasten, Gabriela
Witte, Torsten
author_sort Ernst, Diana
collection PubMed
description Although several risk factors exist for acute coronary syndrome (ACS) no biomarkers for survival or risk of re-infarction have been validated. Previously, reduced serum concentrations of anti-ß(1)AR Ab have been implicated in poorer ACS outcomes. This study further evaluates the prognostic implications of anti-ß(1)AR-Ab levels at the time of ACS onset. Serum anti-ß(1)AR Ab concentrations were measured in randomly selected patients from within the PLATO cohort. Stratification was performed according to ACS event: ST-elevation myocardial infarct (STEMI) vs. non-ST elevation myocardial infarct (NSTEMI). Antibody concentrations at ACS presentation were compared to 12-month all-cause and cardiovascular mortality, as well as 12-month re-infarction. Sub-analysis, stratifying for age and the correlation between antibody concentration and conventional cardiac risk-factors was subsequently performed. Serum anti-ß(1)AR Ab concentrations were measured in 400/799 (50%) STEMI patients and 399 NSTEMI patients. Increasing anti-ß(1)AR Ab concentrations were associated with STEMI (p = 0.001). Across all ACS patients, no associations between anti-ß(1)AR Ab concentration and either all-cause cardiovascular death or myocardial re-infarction (p = 0.14) were evident. However among STEMI patients ≤60 years with anti-ß(1)AR Ab concentration <median higher rates of re-infarction were observed, compared to those with anti-ß(1)AR Ab concentrations > median (14/198 (7.1%) vs. 2/190 (1.1%)); p = 0.01). Similarly, the same sub-group demonstrated greater risk of cardiovascular death in year 1, including re-infarction and stroke (22/198 (11.1%) vs. 10/190 (5.3%); p = 0.017). ACS Patients ≤60 years, exhibiting lower concentrations of ß(1)AR Ab carry a greater risk for early re-infarction and cardiovascular death. Large, prospective studies quantitatively assessing the prognostic relevance of Anti-ß(1)AR Ab levels should be considered.
format Online
Article
Text
id pubmed-6787077
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-67870772019-10-17 Lowered anti-beta1 adrenergic receptor antibody concentrations may have prognostic significance in acute coronary syndrome Ernst, Diana Westerbergh, Johan Sogkas, Georgios Jablonka, Alexandra Ahrenstorf, Gerrit Schmidt, Reinhold Ernst Heidecke, Harald Wallentin, Lars Riemekasten, Gabriela Witte, Torsten Sci Rep Article Although several risk factors exist for acute coronary syndrome (ACS) no biomarkers for survival or risk of re-infarction have been validated. Previously, reduced serum concentrations of anti-ß(1)AR Ab have been implicated in poorer ACS outcomes. This study further evaluates the prognostic implications of anti-ß(1)AR-Ab levels at the time of ACS onset. Serum anti-ß(1)AR Ab concentrations were measured in randomly selected patients from within the PLATO cohort. Stratification was performed according to ACS event: ST-elevation myocardial infarct (STEMI) vs. non-ST elevation myocardial infarct (NSTEMI). Antibody concentrations at ACS presentation were compared to 12-month all-cause and cardiovascular mortality, as well as 12-month re-infarction. Sub-analysis, stratifying for age and the correlation between antibody concentration and conventional cardiac risk-factors was subsequently performed. Serum anti-ß(1)AR Ab concentrations were measured in 400/799 (50%) STEMI patients and 399 NSTEMI patients. Increasing anti-ß(1)AR Ab concentrations were associated with STEMI (p = 0.001). Across all ACS patients, no associations between anti-ß(1)AR Ab concentration and either all-cause cardiovascular death or myocardial re-infarction (p = 0.14) were evident. However among STEMI patients ≤60 years with anti-ß(1)AR Ab concentration <median higher rates of re-infarction were observed, compared to those with anti-ß(1)AR Ab concentrations > median (14/198 (7.1%) vs. 2/190 (1.1%)); p = 0.01). Similarly, the same sub-group demonstrated greater risk of cardiovascular death in year 1, including re-infarction and stroke (22/198 (11.1%) vs. 10/190 (5.3%); p = 0.017). ACS Patients ≤60 years, exhibiting lower concentrations of ß(1)AR Ab carry a greater risk for early re-infarction and cardiovascular death. Large, prospective studies quantitatively assessing the prognostic relevance of Anti-ß(1)AR Ab levels should be considered. Nature Publishing Group UK 2019-10-10 /pmc/articles/PMC6787077/ /pubmed/31601947 http://dx.doi.org/10.1038/s41598-019-51125-9 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Ernst, Diana
Westerbergh, Johan
Sogkas, Georgios
Jablonka, Alexandra
Ahrenstorf, Gerrit
Schmidt, Reinhold Ernst
Heidecke, Harald
Wallentin, Lars
Riemekasten, Gabriela
Witte, Torsten
Lowered anti-beta1 adrenergic receptor antibody concentrations may have prognostic significance in acute coronary syndrome
title Lowered anti-beta1 adrenergic receptor antibody concentrations may have prognostic significance in acute coronary syndrome
title_full Lowered anti-beta1 adrenergic receptor antibody concentrations may have prognostic significance in acute coronary syndrome
title_fullStr Lowered anti-beta1 adrenergic receptor antibody concentrations may have prognostic significance in acute coronary syndrome
title_full_unstemmed Lowered anti-beta1 adrenergic receptor antibody concentrations may have prognostic significance in acute coronary syndrome
title_short Lowered anti-beta1 adrenergic receptor antibody concentrations may have prognostic significance in acute coronary syndrome
title_sort lowered anti-beta1 adrenergic receptor antibody concentrations may have prognostic significance in acute coronary syndrome
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6787077/
https://www.ncbi.nlm.nih.gov/pubmed/31601947
http://dx.doi.org/10.1038/s41598-019-51125-9
work_keys_str_mv AT ernstdiana loweredantibeta1adrenergicreceptorantibodyconcentrationsmayhaveprognosticsignificanceinacutecoronarysyndrome
AT westerberghjohan loweredantibeta1adrenergicreceptorantibodyconcentrationsmayhaveprognosticsignificanceinacutecoronarysyndrome
AT sogkasgeorgios loweredantibeta1adrenergicreceptorantibodyconcentrationsmayhaveprognosticsignificanceinacutecoronarysyndrome
AT jablonkaalexandra loweredantibeta1adrenergicreceptorantibodyconcentrationsmayhaveprognosticsignificanceinacutecoronarysyndrome
AT ahrenstorfgerrit loweredantibeta1adrenergicreceptorantibodyconcentrationsmayhaveprognosticsignificanceinacutecoronarysyndrome
AT schmidtreinholdernst loweredantibeta1adrenergicreceptorantibodyconcentrationsmayhaveprognosticsignificanceinacutecoronarysyndrome
AT heideckeharald loweredantibeta1adrenergicreceptorantibodyconcentrationsmayhaveprognosticsignificanceinacutecoronarysyndrome
AT wallentinlars loweredantibeta1adrenergicreceptorantibodyconcentrationsmayhaveprognosticsignificanceinacutecoronarysyndrome
AT riemekastengabriela loweredantibeta1adrenergicreceptorantibodyconcentrationsmayhaveprognosticsignificanceinacutecoronarysyndrome
AT wittetorsten loweredantibeta1adrenergicreceptorantibodyconcentrationsmayhaveprognosticsignificanceinacutecoronarysyndrome